139 related articles for article (PubMed ID: 37222312)
21. Polybromo-1 (PBRM1), a SWI/SNF complex subunit is a prognostic marker in clear cell renal cell carcinoma.
da Costa WH; Rezende M; Carneiro FC; Rocha RM; da Cunha IW; Carraro DM; Guimaraes GC; de Cassio Zequi S
BJU Int; 2014 May; 113(5b):E157-63. PubMed ID: 24053427
[TBL] [Abstract][Full Text] [Related]
22. CCL5-dependent mast cell infiltration into the tumor microenvironment in clear cell renal cell carcinoma patients.
Liu T; Xia Q; Zhang H; Wang Z; Yang W; Gu X; Hou T; Chen Y; Pei X; Zhu G; He D; Li L; Xu S
Aging (Albany NY); 2020 Nov; 12(21):21809-21836. PubMed ID: 33177244
[TBL] [Abstract][Full Text] [Related]
23. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
Hakimi AA; Ostrovnaya I; Reva B; Schultz N; Chen YB; Gonen M; Liu H; Takeda S; Voss MH; Tickoo SK; Reuter VE; Russo P; Cheng EH; Sander C; Motzer RJ; Hsieh JJ;
Clin Cancer Res; 2013 Jun; 19(12):3259-67. PubMed ID: 23620406
[TBL] [Abstract][Full Text] [Related]
24. Integrative radiogenomics analysis for predicting molecular features and survival in clear cell renal cell carcinoma.
Zeng H; Chen L; Wang M; Luo Y; Huang Y; Ma X
Aging (Albany NY); 2021 Mar; 13(7):9960-9975. PubMed ID: 33795526
[TBL] [Abstract][Full Text] [Related]
25. Expression of PBRM1 as a prognostic predictor in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitor.
Cai W; Wang Z; Cai B; Yuan Y; Kong W; Zhang J; Chen Y; Liu Q; Huang Y; Huang J; Xue W
Int J Clin Oncol; 2020 Feb; 25(2):338-346. PubMed ID: 31720994
[TBL] [Abstract][Full Text] [Related]
26. The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma.
Nargund AM; Pham CG; Dong Y; Wang PI; Osmangeyoglu HU; Xie Y; Aras O; Han S; Oyama T; Takeda S; Ray CE; Dong Z; Berge M; Hakimi AA; Monette S; Lekaye CL; Koutcher JA; Leslie CS; Creighton CJ; Weinhold N; Lee W; Tickoo SK; Wang Z; Cheng EH; Hsieh JJ
Cell Rep; 2017 Mar; 18(12):2893-2906. PubMed ID: 28329682
[TBL] [Abstract][Full Text] [Related]
27. The SSPN Score, a Novel Scoring System Incorporating PBRM1 Expression, Predicts Postoperative Recurrence for Patients with Non-metastatic Clear Cell Renal Cell Carcinoma.
Ohsugi H; Yoshida T; Ohe C; Ikeda J; Sugi M; Kinoshita H; Tsuta K; Matsuda T
Ann Surg Oncol; 2021 Apr; 28(4):2359-2366. PubMed ID: 32940805
[TBL] [Abstract][Full Text] [Related]
28. BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor.
Eckel-Passow JE; Serie DJ; Cheville JC; Ho TH; Kapur P; Brugarolas J; Thompson RH; Leibovich BC; Kwon ED; Joseph RW; Parker AS
BMC Urol; 2017 Mar; 17(1):19. PubMed ID: 28327121
[TBL] [Abstract][Full Text] [Related]
29. Loss of PBRM1 expression is associated with renal cell carcinoma progression.
Pawłowski R; Mühl SM; Sulser T; Krek W; Moch H; Schraml P
Int J Cancer; 2013 Jan; 132(2):E11-7. PubMed ID: 22949125
[TBL] [Abstract][Full Text] [Related]
30. PBRM1 bromodomains variably influence nucleosome interactions and cellular function.
Slaughter MJ; Shanle EK; McFadden AW; Hollis ES; Suttle LE; Strahl BD; Davis IJ
J Biol Chem; 2018 Aug; 293(35):13592-13603. PubMed ID: 29986887
[TBL] [Abstract][Full Text] [Related]
31. Individual Bromodomains of Polybromo-1 Contribute to Chromatin Association and Tumor Suppression in Clear Cell Renal Carcinoma.
Porter EG; Dykhuizen EC
J Biol Chem; 2017 Feb; 292(7):2601-2610. PubMed ID: 28053089
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma.
Jiang W; Dulaimi E; Devarajan K; Parsons T; Wang Q; Liao L; Cho EA; O'Neill R; Solomides C; Peiper SC; Testa JR; Uzzo R; Yang H
PLoS One; 2016; 11(10):e0164554. PubMed ID: 27764136
[TBL] [Abstract][Full Text] [Related]
33. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.
Ibragimova I; Maradeo ME; Dulaimi E; Cairns P
Epigenetics; 2013 May; 8(5):486-93. PubMed ID: 23644518
[TBL] [Abstract][Full Text] [Related]
34. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma.
Liu XD; Kong W; Peterson CB; McGrail DJ; Hoang A; Zhang X; Lam T; Pilie PG; Zhu H; Beckermann KE; Haake SM; Isgandrova S; Martinez-Moczygemba M; Sahni N; Tannir NM; Lin SY; Rathmell WK; Jonasch E
Nat Commun; 2020 May; 11(1):2135. PubMed ID: 32358509
[TBL] [Abstract][Full Text] [Related]
35. A germline mutation in PBRM1 predisposes to renal cell carcinoma.
Benusiglio PR; Couvé S; Gilbert-Dussardier B; Deveaux S; Le Jeune H; Da Costa M; Fromont G; Memeteau F; Yacoub M; Coupier I; Leroux D; Méjean A; Escudier B; Giraud S; Gimenez-Roqueplo AP; Blondel C; Frouin E; Teh BT; Ferlicot S; Bressac-de Paillerets B; Richard S; Gad S
J Med Genet; 2015 Jun; 52(6):426-30. PubMed ID: 25911086
[TBL] [Abstract][Full Text] [Related]
36. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.
Hakimi AA; Chen YB; Wren J; Gonen M; Abdel-Wahab O; Heguy A; Liu H; Takeda S; Tickoo SK; Reuter VE; Voss MH; Motzer RJ; Coleman JA; Cheng EH; Russo P; Hsieh JJ
Eur Urol; 2013 May; 63(5):848-54. PubMed ID: 23036577
[TBL] [Abstract][Full Text] [Related]
37. Prognostic and clinicopathological value of PBRM1 expression in renal cell carcinoma.
Wang Z; Peng S; Guo L; Xie H; Wang A; Shang Z; Niu Y
Clin Chim Acta; 2018 Nov; 486():9-17. PubMed ID: 30006290
[TBL] [Abstract][Full Text] [Related]
38. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
Brugarolas J
Cancer J; 2013; 19(4):324-32. PubMed ID: 23867514
[TBL] [Abstract][Full Text] [Related]
39. Influence of Contrast Administration on Computed Tomography-Based Analysis of Visceral Adipose and Skeletal Muscle Tissue in Clear Cell Renal Cell Carcinoma.
Paris MT; Furberg HF; Petruzella S; Akin O; Hötker AM; Mourtzakis M
JPEN J Parenter Enteral Nutr; 2018 Sep; 42(7):1148-1155. PubMed ID: 29350403
[TBL] [Abstract][Full Text] [Related]
40. Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma.
Piva F; Giulietti M; Occhipinti G; Santoni M; Massari F; Sotte V; Iacovelli R; Burattini L; Santini D; Montironi R; Cascinu S; Principato G
Oncotarget; 2015 Oct; 6(31):32161-8. PubMed ID: 26452128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
